Arvinas, Inc. (ARVN) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of a loss of $0.86 per share. This compares to loss of $0.97 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 232.56%. A quarter ago, it was expected that this company would post a loss of $1.07 per share when it actually produced a loss of $0.63, delivering a surprise of 41.12%.Over the last four quarters, the company ...

Arvinas (ARVN) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Speaker0 It is now my pleasure to turn today's call over to Arvina's Vice President of Investor Relations, Jeff Boyle. Please go ahead. Speaker1 Thank you, and good morning, everyone. Thanks for joining us. Earlier today, we issued a press release with our first quarter twenty twenty five financial results, which is available in the Investor and Media section of our website at arvinas.com. Joining the call today are John Houston, Arvinas' Chief E ...

Exhibit 99.1 Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update – Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company's first neuroscience program with ARV-102 showing blood- brain barrier penetration and central and peripheral LRRK2 degradation – ARV-102: Oral PROTAC LRRK2 degrader ARV-393: Oral PROTAC BCL6 degrader – Announced the re-prioritization of its vepdegestrant de ...

Core Insights - Arvinas, Inc. presented promising preclinical data for ARV-393, a PROTAC BCL6 degrader, showing strong synergistic antitumor activity in combination with standard-of-care treatments for aggressive B-cell lymphomas [1][2][4] Group 1: Study Findings - ARV-393 demonstrated complete tumor regressions in high-grade B-cell lymphoma and aggressive diffuse large B-cell lymphoma models when combined with standard-of-care chemotherapy and biologics [1][4] - The combination of ARV-393 with R-CHOP chemotherapy resulted in significantly greater tumor growth inhibition compared to R-CHOP or ARV-393 alone, with complete regressions observed in all treated mice [4] - Combinations of ARV-393 with investigational small molecule inhibitors targeting oncogenic drivers like BTK, BCL2, and EZH2 also led to superior tumor growth inhibition and regressions in all treated mice [4] Group 2: Clinical Development - A Phase 1 clinical trial of ARV-393 is currently enrolling patients with relapsed/refractory non-Hodgkin lymphoma, including DLBCL [2][5] - The preclinical data support the potential for broad combinability of ARV-393, providing a rationale for further exploration of combination strategies in lymphoma treatment [2][5] Group 3: Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing therapies based on targeted protein degradation, with a pipeline that includes ARV-393 for non-Hodgkin lymphoma and other investigational drugs for various conditions [6]

– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that data from the global Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant versus fulvestrant in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer will be presented as a late-breaking ...

Core Insights - Arvinas, Inc. announced new preclinical combination data for ARV-393, which will be presented at the AACR Annual meeting, highlighting its potential to be combined with standard lymphoma treatments [1][2] Group 1: Product Information - ARV-393 is an investigational PROteolysis TArgeting Chimera (PROTAC) designed to degrade B-cell lymphoma 6 protein (BCL6), a key driver of B-cell lymphomas [2][4] - The degradation of BCL6 through PROTAC technology aims to address the traditionally undruggable nature of this protein, which plays a significant role in B cell tolerance and proliferation [4] Group 2: Presentation Details - The presentation of ARV-393 will take place on April 28, 2025, at the AACR Annual meeting, with the poster titled "ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma Models" [3] - The session will focus on experimental and molecular therapeutics, specifically under the title "Degraders and Glues 2" [3] Group 3: Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing therapies that utilize the body's natural protein disposal system to selectively degrade disease-causing proteins [5] - The company is advancing multiple investigational drugs, including vepdegestrant for ER+/HER2- breast cancer, ARV-393 for non-Hodgkin lymphoma, and ARV-102 for neurodegenerative disorders [5]

Arvinas, Inc. (ARVN) has been on a downward spiral lately with significant selling pressure. After declining 25.4% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a s ...

Arvinas, Inc. ARVN unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ARV-102.Results from the randomized, double-blind, placebo-controlled single ascending dose (SAD) cohort of the Phase 1 healthy volunteer trial and initial results from the multiple ascending dose (MAD) cohort were shared in a presentation at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases.The Phase 1 trial included SAD cohorts from 10 mg to 200 mg and MAD cohorts of 10 mg ...

Core Insights - Arvinas, Inc. presented data from the first-in-human clinical trial of ARV-102, demonstrating its potential in reducing LRRK2 protein associated with neurodegenerative diseases like Parkinson's disease and progressive supranuclear palsy [1][3][7] Group 1: Clinical Trial Findings - ARV-102 was well tolerated and showed substantial LRRK2 reduction in both central and peripheral systems, indicating effective protein degradation [1][5] - The Phase 1 trial included a single ascending dose (SAD) cohort with doses from 10 mg to 200 mg and a multiple ascending dose (MAD) cohort with doses from 10 mg to 80 mg [2][3] - At doses of 60 mg or higher, ARV-102 achieved over 50% LRRK2 reduction in cerebrospinal fluid (CSF) and over 90% reduction in peripheral blood mononuclear cells (PBMCs) [5][9] Group 2: Safety and Tolerability - No serious adverse events were reported, and the drug was generally safe and well tolerated among healthy volunteers [4][5] - Common treatment-related adverse events included headache (17.1%) and fatigue (8.6%), with procedural pain from lumbar puncture reported in 28.6% of treated individuals [9] Group 3: Pharmacokinetics and Pharmacodynamics - ARV-102 demonstrated dose-dependent increases in exposure in both plasma and CSF, with a median terminal plasma half-life of 73 hours [9] - The drug's pharmacodynamic effects included significant reductions in phospho-Rab10T73 and bis(monoacylglycerol)phosphate (BMP) in urine, indicating engagement with downstream LRRK2 pathways [5][9] Group 4: Future Directions - Arvinas plans to continue the clinical program for ARV-102, with ongoing trials in patients with Parkinson's disease and expectations to present initial data in 2025 [7][10]

Core Insights - Arvinas, Inc. is set to present data from its first-in-human study of ARV-102, a drug targeting LRRK2, at the International Conference on Alzheimer's and Parkinson's Diseases in April 2025 [1][3] - ARV-102 is designed as a PROTAC to degrade LRRK2, which is linked to Parkinson's disease and progressive supranuclear palsy [2][4] - The presentation will focus on the safety, pharmacokinetics, and pharmacodynamics of ARV-102 in healthy males [3] Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing therapies for serious diseases using its PROTAC platform [5] - The company is advancing multiple investigational drugs, including vepdegestrant for breast cancer, ARV-393 for non-Hodgkin lymphoma, and ARV-102 for neurodegenerative disorders [5] - Arvinas is headquartered in New Haven, Connecticut, and aims to improve patient outcomes through innovative protein degradation therapies [5]